| Literature DB >> 27838723 |
Kirsten Bibbins-Domingo1, David C Grossman2, Susan J Curry3, Karina W Davidson4, John W Epling5, Francisco A R García6, Matthew W Gillman7,8, Alex R Kemper9, Alex H Krist10,11, Ann E Kurth12, C Seth Landefeld13, Michael L LeFevre14, Carol M Mangione15, William R Phillips16, Douglas K Owens17, Maureen G Phipps18, Michael P Pignone19.
Abstract
Importance: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults. Objective: To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events. Conclusions and Recommendations: The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater (B recommendation). The USPSTF recommends that clinicians selectively offer low- to moderate-dose statins to adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors and a calculated 10-year CVD event risk of 7.5% to 10% (C recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older (I statement).Entities:
Mesh:
Substances:
Year: 2016 PMID: 27838723 DOI: 10.1001/jama.2016.15450
Source DB: PubMed Journal: JAMA ISSN: 0098-7484 Impact factor: 56.272